Filter Specialty

Submit to journal

Submit To The Journals

Dermatological Cancer

Dermatological Cancer

BRAF-mutant Melanoma – The COLUMBUS Trial
Reinhard Dummer
European Oncology & Haematology. 2018;14(2):78–9 DOI: https://doi.org/10.17925/EOH.2018.14.2.78
Dermatological Cancer

The Evolution of Advanced Melanoma Treatment – is Long-term Survivorship on the Horizon?
Dermatological Cancer

Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
Dermatological Cancer

Paolo A Ascierto, ESMO 2018 – Developments in the Treatment of Advanced Melanoma
Dermatological Cancer

Adjuvant use of Immune Checkpoint Inhibitors After Resection of Advanced Melanoma
Dermatological Cancer

Jeffrey S Weber, ASCO 2018 – Resected Stage III Melanoma and the CheckMate 238 Trial
Dermatological Cancer

Paolo Ascierto, ASCO 2018 – Personalised strategies and advances in the treatment of melanoma
Dermatological Cancer

ESMO 2017 – Jean-Jacques Grob Interview
Dermatological Cancer

ESMO 2017 – Ivan Marquez Rodas Interview
Dermatological Cancer

ESMO 2017 – Dirk Schadendorf Interview
Dermatological Cancer

ESMO 2017 – Mario Mandala Interview
Dermatological Cancer

ESMO 2017 Panel Discussion, Part 5 – Staging and New Staging Guideline
Dermatological Cancer

ESMO 2017 Panel Discussion, Part 4 – BRAF-Positive Melanoma versus Wild Type
Dermatological Cancer

ESMO 2017 Panel Discussion, Part 3 – Benefit–Risk Balance Issues in Metastatic BRAF-Positive Melanoma
Dermatological Cancer

ESMO 2017 Panel Discussion, Part 2 – Discussing Benefit–Risk Balance For Treatment Options With Patients With BRAF-Positive Melanoma
Dermatological Cancer

ESMO 2017 Panel Discussion, Part 1 – BRAK/MEK Inhibitors and Immunotherapy in BRAF-positive Melanoma
Dermatological Cancer

ESMO 2017 – Paolo Ascierto Interview
Dermatological Cancer

Combined BRAF and MEK Inhibition with Vemurafenib and Cobimetinib for Patients with Advanced Melanoma
Antonio M Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella, Paolo A Ascierto
European Oncology & Haematology, 2017;13(1):61-5. DOI: https://doi.org/10.17925/EOH.2017.13.01.1a

Load More Posts

Society Partners & Key Congresses

Quick Links

Other websites from

Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.